OncoViRx is a discovery-stage, pharmaceutical start-up within the University of Pennsylvania’s UPstart program. In collaboration with the University’s Robertson and Winkler Laboratories, we are focused on discovering and developing novel small molecule therapies for the treatment of a range of hematologic malignancies (blood cancers). Specifically, we are working on compounds that inhibit the c-MYC, NF-KB, and Notch1 pathways, and anticipate initial clinical development will be in several sub-types of relapsed/refractory non-Hodgkin’s lymphoma and/or acute myeloid leukemia.READ MORE
Approximately every 3 minutes one person in the United States is diagnosed with a blood cancer.
Approximately every 10 minutes one person in the United States dies from a blood cancer.
An estimated 156,400 people were diagnosed with leukemia, lymphoma, or myeloma in 2014.READ MORE
In collaboration with the University of Pennsylvania, OncoViRx is developing compounds that inhibit the c-MYC, NF-KB, and Notch pathways. Our goal is to develop novel treatments that are efficacious, have reduced short and long term side effect profiles, and are cost effective.READ MORE
The OncoViRx management team brings decades of experience from some of the world’s leading pharmaceutical companies and research institutions.READ MORE